Browsing the "endpoint" Tag

Acadia’s Pimavanserin Narrowly Hits Primary Endpoint in Schizophrenia Study

November 27th, 2019 📆 | 2247 Views ⚑

ACADIA Pharmaceuticals, based in San Diego, announced positive top-line data from its Phase III ADVANCE trial of pimavanserin in schizophrenia.

Tagged with: